LG Chem's strategy is to expand its life sciences business and to reach global markets such as the US and Europe in various therapeutic areas in the upcoming years.
In the global Phase 3 clinical trial, Tigulixostat will be evaluated in 350 adult gout patients with hyperuricemia for safety and efficacy at Month 6 of treatment, and the data will be compared with that of the placebo-controlled group.
The primary end point is the patient ratio reaching below 6mg/dL of serum uric acid concentration after six months of treatment.
Additionally, LG Chem will be submitting an application to the US FDA for a comparative study with 'Allopurinol,' a first line treatment of gout.
The company's strategy is to prove distinguished efficacy and safety for long-term treatment through global clinical trial.
LG Chem aims to enter the global gout market in 2028 after obtaining US FDA approval for Tigulixostat as a first line treatment.
Tigulixostat is an oral drug administered once daily. It inhibits enzymatic activity of 'XO (Xanthine Oxidase),' thereby reducing production of uric acid, which is the primary cause of gout.
Results from the US Phase 2 clinical trial--primary end point set at a challenging level (achieving below 5mg/dL serum uric acid concentration)--confirmed the potential of Tigulixostat as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the placebo group.
According to Coherent Market Insights, the global gout market value is projected to escalate from 2.6bn in 2019 to 4.3bn by 2027 due to the increase of aging and obese population.
Currently, 35m people are diagnosed with gout worldwide and it is estimated that there are 10 m and 14m gout patients in the US and China, respectively.
LG Chem Life Sciences is a business division within LG Chem, engaged in development, manufacturing and global commercialization of pharmaceutical products.
LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases).
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients